Thursday, October 29, 2026, 1 PM-2 PM ET
Hear an expert discuss the evolving role of PD-L1 testing in HNSCC and ovarian cancer.
Webinar presenter Georgios Deftereos, MD, Professor of Pathology, Associate Director of the Clinical Cancer Genomics Laboratory, Director of Molecular Cytopathology, University of California, San Francisco
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Agilent.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 3, 2026, 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.
Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 10, 2026, 1 PM-2 PM ET
Join us for a session to help improve diagnostic accuracy in your practice when scoring HER2 IHC 0 with faint, incomplete membrane staining in ≤10% of tumor cells vs IHC 0 with no membrane staining detected in patients with mBC.
Webinar presenter Jeffrey Gregg, MD, University of Nevada
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.
Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Aug. 19, 2022—Abbott announced that a study published in Lancet Neurology demonstrates the ability of two blood-based biomarkers to predict how a person will recover from traumatic brain injury (TBI) (Korley FK, et al. Lancet Neurol. 2022;21[9]:803–813).
Aug. 17, 2022—BD and Accelerate Diagnostics announced a worldwide commercial collaboration agreement in which BD will offer Accelerate’s rapid testing solution for antibiotic resistance and susceptibility.
Aug. 16, 2022—The FDA granted premarket approval to Thermo Fisher Scientific’s Oncomine Dx Target test as a companion diagnostic to identify patients whose tumors have HER2 (ERBB2)-activating mutations (single nucleotide variants and exon 20 insertion) in non-small cell lung cancer who may be candidates for Enhertu (fam-trastuzumab deruxtecan-nxki).
Aug. 15, 2022—Roche announced that the FDA has approved a label expansion for the Ventana MMR RxDx panel, an immunohistochemistry companion diagnostic test to aid in identifying patients whose solid tumors are deficient in DNA mismatch repair (dMMR) and who may be eligible for Keytruda (pembrolizumab).
August 8, 2022—AstraZeneca and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan) has been approved in the U.S. for the treatment of adult patients with unresectable or metastatic HER2-low (IHC 1+ or IHC 2+/ISH-) breast cancer who have received a prior chemotherapy in the metastatic setting or developed disease recurrence during or within six months of completing adjuvant chemotherapy.
July 29, 2022—The FDA has cleared the BioMérieux Vidas Nephrocheck assay, for use to detect kidney stress in patients at risk of acute kidney injury.
July 27, 2022—CellaVision announced today at the AACC meeting the launch of its Diff-Line by CellaVision, a workflow solution for low-volume hematology laboratories.
July 20, 2022—Roche announced yesterday that the FDA has granted breakthrough device designation to the Elecsys Amyloid Plasma Panel.
July 14, 2022—Bio-Rad Laboratories launched two new Exact Diagnostics negative run controls.
July 13, 2022—Thermo Fisher Scientific announced an agreement with Inpeco S.A. to develop connectivity between the Thermo Scientific Cascadion SM automated liquid chromatography mass spectrometer and the Inpeco FlexLab total laboratory automation system.
